Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556202 · ClinicalTrials.gov registry record · Phase 3
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,936
- Enrollment target
NCT03556202: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT03556202 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,936 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (151% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03556202, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,936 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
Primary Outcome
The sPGA is the physician's determination of the participant's psoriasis (PsO) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response crit
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,936 participants |
| Start Date | 2018-09-03 |
| Est. Completion | 2022-02-07 |
| Phase | Phase 3 |
Why NCT03556202 stopped before completion
NCT03556202 is an interventional study that assigns participants to a tested intervention. Its 1,936 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (151% higher).
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT03556202 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03556202 about?
NCT03556202 is a clinical study titled "A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)". The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT03556202?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,936 participants. The study started on 2018-09-03. Estimated completion is 2022-02-07.
What interventions are being tested in trial NCT03556202?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT03556202?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03556202's enrollment target sits among peer trials
1,936 109th of 2000 higher than 1,892 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI